User Tools

Site Tools

Trace: • prednisolone
basics:start

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
basics:start [2026/02/12 20:50] – [Cytokine-Specific Biologics] andrew2393cnsbasics:start [2026/02/12 21:11] (current) – [High-Yield Framework] andrew2393cns
Line 18: Line 18:
 ---- ----
  
 +===== High-Yield Framework =====
 +
 +  * Innate immunity initiates inflammation.
 +  * Adaptive immunity provides specificity and memory.
 +  * Th1/Th17 drive autoimmune inflammation.
 +  * Th2 drives allergic disease.
 +  * COX pathway → prostaglandins.
 +  * 5-LOX pathway → leukotrienes.
 +  * NSAIDs block COX.
 +  * COX-2 inhibitors selectively block inflammatory COX-2.
 +  * Leukotriene modifiers block bronchoconstrictive leukotrienes.
 +  * Corticosteroids suppress upstream inflammatory transcription.
 +  * Biologics target specific cytokines.
 +
 +----
 ===== I. Core Immune Physiology ===== ===== I. Core Immune Physiology =====
  
Line 48: Line 63:
   * Th1 → [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]   * Th1 → [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]
   * Th2 → [[allergy:clinical:allergic_rhinitis|Allergic Disease]] / [[respiratory:clinical:asthma|Asthma]]   * Th2 → [[allergy:clinical:allergic_rhinitis|Allergic Disease]] / [[respiratory:clinical:asthma|Asthma]]
-  * Th17 → [[dermatology:clinical:psoriasis|Psoriasis]] / [[gastroenterology:clinical:inflammatory_bowel_disease|IBD]]+  * Th17 → [[dermatology:clinical:psoriasis|Psoriasis]] / [[gastroenterology:clinical:ibd|IBD]]
   * Treg → immune tolerance   * Treg → immune tolerance
  
Line 76: Line 91:
  
   * [[respiratory:clinical:asthma|Asthma]]   * [[respiratory:clinical:asthma|Asthma]]
-  * [[gastroenterology:clinical:inflammatory_bowel_disease|IBD]]+  * [[gastroenterology:clinical:ibd|IBD]]
   * [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]   * [[rheumatology:clinical:rheumatoid_arthritis|Rheumatoid Arthritis]]
   * [[dermatology:clinical:psoriasis|Psoriasis]]   * [[dermatology:clinical:psoriasis|Psoriasis]]
Line 129: Line 144:
 Drug modulation: Drug modulation:
  
-  * [[allergy:drugs:second_generation_antihistamines|Second Generation Antihistamines]] +  * [[allergy:drug_classes:first_generation_h1|First Generation Antihistamines]] 
-  * First-generation antihistamines+  * [[allergy:drug_classes:second_generation_h1|Second Generation Antihistamines]]
   * [[endocrine:drug_classes:corticosteroids|Corticosteroids]]   * [[endocrine:drug_classes:corticosteroids|Corticosteroids]]
   * Epinephrine   * Epinephrine
Line 141: Line 156:
 ---- ----
  
-==== Complement Cascade =====+==== Complement Pathway =====
  
-  * [[immunology:complement_system|Complement System]]+Drug Modulation
  
-Drug modulation: +  * [[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]]
- +
-  * [[immunology:complement_inhibitors|Complement Inhibitors]]+
  
 ---- ----
Line 171: Line 184:
 ---- ----
  
-==== Cytokine-Specific Biologics ====+==== Targeted Immune Therapies ====
  
-===== Anti-TNF Agents =====+[[immunology:biologics:anti_tnf_agents|Anti-TNF Agents]]
  
   * [[immunology:biologics:infliximab|Infliximab]]   * [[immunology:biologics:infliximab|Infliximab]]
   * [[immunology:biologics:adalimumab|Adalimumab]]   * [[immunology:biologics:adalimumab|Adalimumab]]
 +  * [[immunology:biologics:etanercept|Etanercept]]
 +  * [[immunology:biologics:certolizumab|Certolizumab]]
 +  * [[immunology:biologics:golimumab|Golimumab]]
  
-Class overview: +-----
-  * [[immunology:biologics:anti_tnf_agents|Anti-TNF Agents]]+
  
----- +[[immunology:biologics:anti_il_12_23_agents|Anti-IL-12/23 Agents]]
- +
-===== Anti-IL-12/23 Agents =====+
  
   * [[immunology:biologics:ustekinumab|Ustekinumab]]   * [[immunology:biologics:ustekinumab|Ustekinumab]]
  
-Class overview: +-----
-  * [[immunology:biologics:anti_il_12_23_agents|Anti-IL-12/23 Agents]]+
  
-----+[[immunology:drug_classes:il_23_inhibitors|IL-23 Inhibitors]]
  
-===== Anti-Integrin Agents =====+  * [[immunology:biologics:guselkumab|Guselkumab]] 
 +  * [[immunology:biologics:risankizumab|Risankizumab]] 
 +  * [[immunology:biologics:tildrakizumab|Tildrakizumab]] 
 +  * [[immunology:biologics:mirikizumab|Mirikizumab]] 
 + 
 +----- 
 + 
 +[[immunology:drug_classes:il_17_inhibitors|IL-17 Inhibitors]] 
 + 
 +  * [[immunology:biologics:secukinumab|Secukinumab]] 
 +  * [[immunology:biologics:ixekizumab|Ixekizumab]] 
 +  * [[immunology:biologics:brodalumab|Brodalumab]] 
 +  * [[immunology:biologics:bimekizumab|Bimekizumab]] 
 + 
 +----- 
 + 
 +[[immunology:drug_classes:il_6_inhibitors|IL-6 Inhibitors]] 
 + 
 +  * [[immunology:biologics:tocilizumab|Tocilizumab]] 
 +  * [[immunology:biologics:sarilumab|Sarilumab]] 
 +  * [[immunology:biologics:siltuximab|Siltuximab]] 
 + 
 +----- 
 + 
 +[[immunology:drug_classes:il_1_inhibitors|IL-1 Inhibitors]] 
 + 
 +  * [[immunology:biologics:anakinra|Anakinra]] 
 +  * [[immunology:biologics:canakinumab|Canakinumab]] 
 +  * [[immunology:biologics:rilonacept|Rilonacept]] 
 + 
 +----- 
 + 
 +[[immunology:drug_classes:anti_ige_agents|Anti-IgE Agents]] 
 + 
 +  * [[immunology:biologics:omalizumab|Omalizumab]] 
 + 
 +----- 
 + 
 +[[immunology:biologics:anti_integrin_agents|Anti-Integrin Agents]]
  
   * [[immunology:biologics:vedolizumab|Vedolizumab]]   * [[immunology:biologics:vedolizumab|Vedolizumab]]
 +  * [[immunology:biologics:natalizumab|Natalizumab]]
  
-Class overview: +-----
-  * [[immunology:biologics:anti_integrin_agents|Anti-Integrin Agents]]+
  
-----+[[immunology:drug_classes:jak_inhibitors|JAK Inhibitors]]
  
-===== Other Targeted Immune Therapies =====+  * [[immunology:drugs:tofacitinib|Tofacitinib]] 
 +  * [[immunology:drugs:baricitinib|Baricitinib]] 
 +  * [[immunology:drugs:upadacitinib|Upadacitinib]] 
 +  * [[immunology:drugs:filgotinib|Filgotinib]] (non-US approval varies) 
 +  * [[immunology:drugs:ruxolitinib|Ruxolitinib]]
  
-  * [[immunology:drug_classes:il_1_inhibitors|IL-1 Inhibitors]] +-----
-  * [[immunology:drug_classes:il_6_inhibitors|IL-6 Inhibitors]] +
-  * [[immunology:drug_classes:il_17_inhibitors|IL-17 Inhibitors]] +
-  * [[immunology:drug_classes:il_23_inhibitors|IL-23 Inhibitors]] +
-  * [[immunology:drug_classes:jak_inhibitors|JAK Inhibitors]] +
-  * [[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]] +
-  * [[immunology:drug_classes:costimulation_blockers|Costimulation Blockers]] +
-  * [[immunology:drug_classes:anti_ige_agents|Anti-IgE Agents]]+
  
-===== High-Yield Framework =====+[[immunology:drug_classes:complement_inhibitors|Complement Inhibitors]] 
 + 
 +  * [[immunology:biologics:eculizumab|Eculizumab]] 
 +  * [[immunology:biologics:ravulizumab|Ravulizumab]] 
 +  * [[immunology:biologics:avacopan|Avacopan]] 
 +  * [[immunology:biologics:pegcetacoplan|Pegcetacoplan]] 
 + 
 +----- 
 + 
 +[[immunology:drug_classes:costimulation_blockers|Costimulation Blockers]] 
 + 
 +  * [[immunology:biologics:abatacept|Abatacept]]
  
-  * Innate immunity initiates inflammation. 
-  * Adaptive immunity provides specificity and memory. 
-  * Th1/Th17 drive autoimmune inflammation. 
-  * Th2 drives allergic disease. 
-  * COX pathway → prostaglandins. 
-  * 5-LOX pathway → leukotrienes. 
-  * NSAIDs block COX. 
-  * COX-2 inhibitors selectively block inflammatory COX-2. 
-  * Leukotriene modifiers block bronchoconstrictive leukotrienes. 
-  * Corticosteroids suppress upstream inflammatory transcription. 
-  * Biologics target specific cytokines. 
basics/start.1770929416.txt.gz · Last modified: by andrew2393cns